Argent Biopharma Limited has released a press release.
Mxc well positioned for tga down-schedule of cbd products
Filed with ASX · · 2 pages · English
6ix is checking which company filed this.
Earlier from Argent Biopharma
- $15M finance facility to fund revenue growth for key markets
- Appendix 4E and Preliminary Unaudited Financial Report
- JV to be established for registration of ArtemiC in Russia
- COVID-19 Interim Trial Results Meet All Primary Objectives
- UK distribution agreement signed for MGC Pharma medicines
Later from Argent Biopharma
- Mxc welcomes new FCA guidance for cannabis sector in the UK
- Update on ArtemiC phase II trial on COVID-19 patients
- MGC pharma launches CannEpil app
- First high THC products shipped direct to Brazil patients
- ArtemiC histology on rats confirm no pathological impact
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma